Monoclonal Antibody Microarray Assesses Multiple Protein Levels in Plasma

A monoclonal antibody microarray was developed to assess the level of multiple proteins simultaneously in human plasma.

Using the QuantiPlasma array it is possible to assess directly the plasma proteome of normal and disease state plasma samples for the identification of novel biomarkers. Each kit contains 300 unique monoclonal antibodies that can be assessed simultaneously using Biochip Array Technology.

Currently biomarker discovery by mass spectrometry is an expensive and laborious method, with limitations in reproducibility and sensitivity due to the wide range of protein concentrations in plasma and extensive processing requirements. Biomarker validation and follow-on studies can also be impeded by a lack of available immunoaffinity reagents.

Randox Pharma Services (Crumlin, United Kingdom) designed and developed the QuantiPlasma array. The company invested in developing solutions for biomarker discovery because of their broad range of applications for the diagnosis, prognosis, and monitoring of disease progression and the monitoring of clinical responses. The solutions should lead to therapeutic intervention and personalized medicine.

Related Links:
Randox Pharma Services